TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

被引:123
作者
Zenz, T. [1 ]
Vollmer, D. [1 ]
Trbusek, M. [2 ,3 ]
Smardova, J. [2 ,3 ]
Benner, A. [4 ]
Soussi, T. [5 ,6 ]
Helfrich, H. [1 ]
Heuberger, M. [1 ]
Hoth, P. [1 ]
Fuge, M. [1 ]
Denzel, T. [1 ]
Haebe, S. [1 ]
Malcikova, J. [2 ,3 ]
Kuglik, P. [2 ,3 ]
Truong, S. [7 ]
Patten, N. [7 ]
Wu, L. [7 ]
Oscier, D. [8 ]
Ibbotson, R. [8 ]
Gardiner, A. [8 ]
Tracy, I. [8 ]
Lin, K. [9 ]
Pettitt, A. [9 ]
Pospisilova, S. [2 ,3 ]
Mayer, J. [2 ,3 ]
Hallek, M. [10 ]
Doehner, H. [1 ]
Stilgenbauer, S. [1 ]
机构
[1] Univ Ulm, Dept Internal Med, D-89081 Ulm, Germany
[2] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic
[3] Masaryk Univ, Fac Med, Brno, Czech Republic
[4] German Canc Res Ctr, D-6900 Heidelberg, Germany
[5] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden
[6] Univ Paris 06, Paris, France
[7] Roche Mol Syst, Pleasanton, CA USA
[8] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England
[9] Univ Liverpool, Dept Haematol, Liverpool L69 3BX, Merseyside, England
[10] Univ Cologne, Dept Internal Med 1, Cologne, Germany
关键词
CLL; genetics; 17p deletion; p53; TP53; mutation;
D O I
10.1038/leu.2010.208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL. We report on 268 mutations in 254 patients with CLL. Missense mutations appeared in 74% of cases compared with deletions and insertions (20%), nonsense (4%) and splice site (2%) mutations. The majority (243 of 268) of mutations were located in the DNA-binding domain. Transitions were found in 131 of 268 mutations, with only 41 occurring at methylated CpG sites (15%), suggesting that transitions at CpGs are uncommon. The codons most frequently mutated were at positions 175, 179, 248 and 273; in addition, we detected a common 2-nt deletion in the codon 209. Most mutations (199 of 259) were accompanied by deletion of the other allele (17p-). Interestingly, trisomy 12 (without 17p-) was only found in one of 60 cases with TP53 mutation (without 17p-) compared with 60 of 16 in the cohort without mutation (P=0.006). The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment. Leukemia (2010) 24, 2072-2079; doi:10.1038/leu.2010.208; published online 23 September 2010
引用
收藏
页码:2072 / 2079
页数:8
相关论文
共 39 条
[1]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[2]   Spectrum of p53 mutations in low-grade B-cell malignancies [J].
Bromidge, T. ;
Johnson, S. ;
Howe, D. .
LEUKEMIA, 2008, 22 (05) :1071-1073
[3]   p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis [J].
Cordone, I ;
Masi, S ;
Mauro, FR ;
Soddu, S ;
Morsilli, O ;
Valentini, T ;
Vegna, ML ;
Guglielmi, C ;
Mancini, F ;
Giuliacci, S ;
Sacchi, A ;
Mandelli, F ;
Foa, R .
BLOOD, 1998, 91 (11) :4342-4349
[4]  
DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1
[5]   The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype [J].
Dicker, F. ;
Herholz, H. ;
Schnittger, S. ;
Nakao, A. ;
Patten, N. ;
Wu, L. ;
Kern, W. ;
Haferlach, T. ;
Haferlach, C. .
LEUKEMIA, 2009, 23 (01) :117-124
[6]   P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS [J].
DOHNER, H ;
FISCHER, K ;
BENTZ, M ;
HANSEN, K ;
BENNER, A ;
CABOT, G ;
DIEHL, D ;
SCHLENK, R ;
COY, J ;
STILGENBAUER, S ;
VOLKMANN, M ;
GALLE, PR ;
POUSTKA, A ;
HUNSTEIN, W ;
LICHTER, P .
BLOOD, 1995, 85 (06) :1580-1589
[7]  
ELROUBY S, 1993, BLOOD, V82, P3452
[8]  
FENAUX P, 1992, LEUKEMIA, V6, P246
[9]   A SIMPLE P53 FUNCTIONAL ASSAY FOR SCREENING CELL-LINES, BLOOD, AND TUMORS [J].
FLAMAN, JM ;
FREBOURG, T ;
MOREAU, V ;
CHARBONNIER, F ;
MARTIN, C ;
CHAPPUIS, P ;
SAPPINO, AP ;
LIMACHER, JM ;
BRON, L ;
BENHATTAR, J ;
TADA, M ;
VAN MEIR, EG ;
ESTREICHER, A ;
IGGO, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) :3963-3967
[10]   Structural biology of the tumor suppressor p53 [J].
Joerger, Andreas C. ;
Fersht, Alan R. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2008, 77 :557-582